Table 3. Number of significant Type I, II, and III perturbagens found in each cancer.
| Cancer | Type I | Type II | Type III | Total Sex-Specific |
|---|---|---|---|---|
| LIHC | 432 | 207 | 13 | 639 |
| LUAD | 175 | 243 | 134 | 418 |
| LUSC | 214 | 153 | 153 | 367 |
| KIRC | 0 | 312 | 1 | 312 |
| HNSC | 0 | 236 | 33 | 236 |
| KICH | 0 | 232 | 0 | 232 |
| THCA | 0 | 0 | 3 | 0 |
The table summarizes the number of significant perturbagens of each type in each cancer, based on an empirical BH-value threshold of 0.05 and an additional significance threshold magnitude of 90 for Type III drugs only. BH-values were calculated through permutation analysis (see Materials and methods). The “total sex-specific” column indicates the number of sex-specific (that is, Type I and II) perturbagens in each cancer.